Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
about
RAS isoforms and mutations in cancer at a glanceRationale for RAS mutation-tailored therapies.Insights into cancer severity from biomolecular interaction mechanisms.Rare codons capacitate Kras-driven de novo tumorigenesis.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsSearching for the Chokehold of NRAS Mutant Melanoma.Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.RASopathy Gene Mutations in Melanoma.Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.Genetically engineered mouse models of melanoma.Playing Polo-Like Kinase in NRAS-Mutant Melanoma.A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.RAS variant signallingInterrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
P2860
Q28070394-E8A7BB43-EA74-4179-9A56-5ECC05C3FE46Q30244673-AF8A4BAD-127A-42AB-9C3E-2EC8326DCD3AQ30393703-B4E5052A-03E5-4844-94C0-39E3BB1796A4Q35242568-A86DA12A-3863-4D70-82B0-3510F0CCCC11Q36054290-9B31E077-F0AC-49EF-AA39-0E7021C5EF0AQ36218706-104D157E-9DC1-4ADB-B5D0-85B526C2E3FFQ36916468-ACB706B7-F09F-44FB-9BE7-DC99FE26E3EEQ37038604-A8EE1FF9-F737-49BD-B755-C67AE09C47ACQ37457602-93255BE7-2EF4-4759-A99D-2803956CE209Q37651582-AE46038C-8C3A-4BA8-89D6-295C95982005Q37695704-A4271D1C-999F-4274-9614-9F15187A5C92Q38272701-CA199320-5947-4717-AA8A-1AB13B5F61DAQ38773915-4A0D3735-ACB8-4213-9386-B49F71D6C4BCQ38847120-052E319F-03D3-4A91-AEB1-E780EA3AD512Q39048659-BCEDF864-BDEA-455E-B8D2-0185500FC9ECQ39329577-5B33A55B-41B6-4CC8-913F-3F5469440AD1Q41875182-C80437AE-CC3B-40D1-9DD7-60F57A0A9CACQ42803237-721B3402-F9EC-4A9C-9947-A496866C99F5Q46901200-660E0A10-53E0-405E-85CC-8DB165FE6B0CQ48092505-6A61B243-D5F7-40E4-9105-4CA7FACB761CQ52591043-629D89CC-E7BB-4F2E-8A3C-F5F05CB19725Q52657766-9572AEE1-7EC8-4594-8C6E-4AD1C82D2507Q57033842-0E43536D-350F-45C9-B997-5E05D03C4CA8Q58759673-A08C6E34-6D7B-4E83-A689-8768D62F6C1B
P2860
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
@en
type
label
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
@en
prefLabel
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
@en
P2093
P2860
P1433
P1476
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
@en
P2093
Brit L Martin
Bruce C Baguley
Christin E Burd
Daniel C Zedek
David B Darr
George P Souroullas
James E Gillahan
Kailing Fu
Kelly S Clark
Meriam A Waqas
P2860
P304
P356
10.1158/2159-8290.CD-14-0729
P577
2014-09-24T00:00:00Z